Incyte Data to Be Highlighted in ESMO 2026 Madrid

Key Takeaways

• Incyte plans six oncology presentations at ESMO 2026 in Madrid, including four rapid oral Phase 1 readouts.
• KRAS G12D inhibitor INCB161734 and TGFβR2×PD-1 bispecific INCA33890 are also in ongoing Phase 3 first-line programs for PDAC and MSS colorectal cancer, respectively.
• A retifanlimab poster will report final overall survival from Phase 3 POD1UM-303/InterAACT-2 in advanced squamous anal cancer (NCT04472429).
• This is a calendar disclosure; detailed response rates and survival curves are not yet released.

Incyte ESMO 2026 presentations at a glance

Field	Detail
Company	Incyte (Nasdaq: INCY)
Meeting	ESMO Congress 2026, Madrid, 23–27 October 2026
Disclosure date	17 July 2026 (Business Wire / Incyte investor release)
Presentation count	Six total; four rapid oral, two posters
Key assets	INCB161734, INCA33890, INCB123667, retifanlimab
EU angle	Data debut at Europe’s flagship oncology congress in Madrid

What did Incyte announce for ESMO 2026?

On 17 July 2026, Incyte said it will highlight data from several oncology programs in six presentations at ESMO Congress 2026 in Madrid. Four of those slots are rapid oral presentations of new Phase 1 solid-tumor data.

According to Incyte’s 17 July 2026 Business Wire release, the company is focusing on difficult-to-treat settings such as KRAS G12D-mutant pancreatic and colorectal cancers, microsatellite-stable (MSS) colorectal cancer, and recurrent epithelial ovarian cancer.

Which rapid oral abstracts are scheduled in Madrid?

The company listed four rapid oral abstracts with session times in Central European Time:

• INCB161734 ± cetuximab in advanced/metastatic colorectal cancer — Sunday 25 October, 08:30–10:00 CET (Abstract #1007RO).
• INCB161734 plus chemotherapy in advanced/metastatic pancreatic ductal adenocarcinoma — Monday 26 October, 14:45–16:15 CET (Abstract #3137RO).
• INCA33890 with standard-of-care therapies in MSS colorectal cancer — Saturday 24 October, 08:30–10:00 CET (Abstract #1954RO).
• INCB123667 (CDK2) with bevacizumab in recurrent epithelial ovarian cancer — Friday 23 October, 16:15–17:45 CET (Abstract #1241RO).

The same slate is mirrored on Incyte’s investor news release.

How do the KRAS G12D and TGFβR2×PD-1 programs fit a European oncology agenda?

ESMO remains the primary autumn venue where European clinicians first see mid-stage solid-tumor datasets. Incyte said oral KRAS G12D inhibitor INCB161734 and TGFβR2×PD-1 bispecific INCA33890 are already in ongoing Phase 3 first-line programs for advanced PDAC and MSS colorectal cancer, respectively.

That means Madrid audiences will be watching whether Phase 1 combination signals support the Phase 3 designs already under way — not only whether early monotherapy activity looks promising. For EU practice, KRAS G12D PDAC and MSS CRC are high-need populations where oral targeted agents and next-generation immuno-oncology bispecifics are closely tracked.

What else is Incyte presenting besides the rapid orals?

Two poster presentations round out the slate. One reports final overall survival from POD1UM-303/InterAACT-2, the Phase 3 study of retifanlimab plus carboplatin-paclitaxel in first-line advanced squamous anal cancer (Abstract #3536P; Sunday 25 October).

That trial is registered as NCT04472429 on ClinicalTrials.gov, a completed Phase 3 study sponsored by Incyte that enrolled about 308 participants. A second poster is a trial-in-progress abstract for MAESTRA 3 (GOG-3146; ENGOT-OV106), a Phase 3 maintenance study of INCB123667 with bevacizumab versus bevacizumab alone in cyclin E1-overexpressing advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (Abstract #1336TiP).

Why Madrid timing matters for EU watchers

Holding the disclosure three months before a Madrid congress gives European investigators, payers, and hospital formulary teams a clear calendar for when Phase 1 numbers may land. It also situates Incyte’s solid-tumor expansion inside Europe’s busiest oncology week rather than a US-only meeting cycle.

For retifanlimab, the final OS poster is especially relevant in Europe because squamous anal carcinoma care pathways already incorporate systemic chemo backbones; any survival update will be read against that standard. For INCB161734 and INCA33890, the EU question is whether early combination data justify continued Phase 3 investment in first-line PDAC and MSS CRC.

What remains unproven until ESMO 2026

The July 2026 release confirms presentation titles, abstract numbers, and session times. It does not publish objective response rates, duration of response, grade ≥3 adverse-event rates, or overall survival hazard ratios for the Phase 1 rapid oral programs.

Readers should treat the current disclosure as a verified presentation calendar, not as a clinical readout. Efficacy and safety claims should wait for the Madrid presentations and any peer-reviewed or congress-associated primary publications.

Related NovaPharma coverage

• Truqap US approval in PTEN-deficient metastatic prostate cancer
• Vanda Pharmaceuticals EMA orphan drug designation opinion
• EU Commission and EMA 2026 drug report key findings

Frequently Asked Questions

Primary Sources

1. Incyte Business Wire release — ESMO 2026 presentation slate (17 July 2026)
2. Incyte investor release — four rapid oral presentations at ESMO 2026
3. ClinicalTrials.gov NCT04472429 — POD1UM-303/InterAACT-2 (retifanlimab)